

Notice of Extraordinary General Meeting of Implantica MediSwiss AG

The shareholders of Implantica MediSwiss AG, reg. no. FL-0002.542.008-4, are hereby given notice of the extraordinary general meeting on Friday, September 17, 2021, at 14:00 CET.

To protect the health and safety of all participants in connection with the spread of COVID-19, the extraordinary general meeting on September 17, 2021, will be reduced to the legally required minimum, in accordance with the measures laid down in Article 5 of the Ordinance of June 25, 2020 of the Liechtenstein Government regarding measures against the Corona Virus (COVID-19; LGBl 2020/206) and Article 11 of the Act of April 8, 2020 on accompanying measures in judicial and administrative procedures in the context of COVID-19 (COVID-19-VJBG; LGBl 2020/136). The EGM will take place without the personal participation of shareholders and only the statutorily required people will attend the meeting, which will include representation from the Amt für Justiz in Liechtenstein. The meeting process will include control that the meeting was duly convened and control of the shareholder and voting lists..

Shareholders will be able to vote by submitting their voting form to the Independent Proxy (Article 11 para. 4 lit. b COVID-19-VJBG). Furthermore, shareholders are invited to post their comments and questions to the company via the email address investorrelations@implantica.com before September 17, 2021.

Agenda items

The following agenda items are scheduled for the Annual General Meeting ("AGM"):

1. Approval of the proposed merger plan for the merger of Implantica MediSwiss AG as the transferring company into Implantica AG as the acquiring company (downstream merger)

The following documents will be available for review at the Company's headquarters, Landstrasse 1, Vaduz and on the company's website www.implanticamediswiss.com:

- the merger plan
- the annual accounts and the annual reports of the merging companies Implantica AG and Implantica MediSwiss AG for the last three financial years
- the half-year financial reports for 2021 ending June 30, 2021 of the merging companies Implantica AG (unaudited) and Implantica MediSwiss AG (audited)
- the merger report by the board of directors
- the expert report of Deloitte.

Proposal of the Board of Directors:

The Board of Directors proposes to approve the merger plan dated August 17, 2021 between Implantica MediSwiss AG and Implantica AG which is included as an attachment.

2. Confirmation of the board of directors' proposal for Implantica MediSwiss AG to vote at the Extraordinary General Meeting of Implantica AG on September 17, 2021, accepting a contribution from the main shareholder of assets valued at EUR 117 million to the reserves (without monetary compensation) and an amendment of the Implantica AG Articles of Association to perform a stock split in the class B shares, as has been performed in Implantica MediSwiss AG

Confirm the board's decision to accept a contribution to the reserves (conditional on the split) of 51% of the shares of MedicalTree Swiss AG, valued at EUR 117 million by one of the big four auditors, subject to the amendment of the Implantica AG Articles of Association to perform a stock split in the class B shares of Implantica AG as a condition subsequent. Support the decision to amend the Implantica AG Articles of Association to perform a stock split in the class B shares, thereby reflecting the status of the transferring company, Implantica MediSwiss AG, subject to the registration of the merger between Implantica MediSwiss AG and Implantica AG in the Liechtenstein commercial register as a condition precedent. This voting confirmation for the Implantica AG EGM is provided at the same time as the merger and does not affect the time plan of the merger nor that the Implantica MediSwiss shareholders exchange their shareholding to the listed Implantica AG.

Proposal of the Board of Directors:

The Board of Directors proposes to confirm the acceptance of a contribution from the main shareholder of EUR 117 million to the reserves (without monetary compensation) and to approve a stock split in the class B shares for Implantica AG (subject to the respective conditions outlined above).

General remarks

Only shareholders who are registered with a right to vote on September 10, 2021 are entitled to vote at the Extraordinary General Shareholders' Meeting or to appoint a proxy.

Representation

Shareholders can be represented as follows at the Extraordinary General Shareholders' Meeting: The Board of Directors has appointed the Independent Proxy, Mr. Philipp Wanger, Attorney-at-law, Neugasse 17, 9490 Vaduz (Liechtenstein) for the upcoming Extraordinary General Meeting. Any shareholder wishing to nominate the independent shareholders' representative as proxy should complete the voting slip, add any written voting instructions and send the slip together with the signed Shareholder Confirmation to Mr. Wanger no later than **September 13, 2021**. Unless specifically instructed otherwise, the independent shareholders' representative will cast all such proxy votes received in accordance with the recommendations of the Board of Directors.

Minutes

The minutes of the Extraordinary General Shareholders' Meeting will be available for review from October 1, 2021 at the Company's headquarters, Landstrasse 1, Vaduz.

Implantica MediSwiss AG

The Board of Directors
August 17, 2021